
ALT This image shows a forest plot showing the robustness of the primary analysis results. Subgroups include definite treatment failure, definite or probable treatment failure, and definite, probable, or possible treatment failure. Hazard ratios with 95% confidence intervals are displayed, indicating whether a short duration is better than a long duration. A red line indicates the noninferiority margin.

ALT Two panels showing the primary efficacy and safety end points. Panel A is a bar graph that shows the median number of days alive without antibiotic therapy for infective endocarditis or bacteremia within 6 months after randomization (the primary efficacy end point) among patients in the tailored-therapy and standard-therapy groups. Panel B shows the Kaplan–Meier estimates of the probability of a composite of death from any cause, unplanned cardiac surgery, or symptomatic embolic events within 6 months after randomization (the primary safety end point).

ALT The image is a graph showing the posterior probability distribution of the treatment effect for cefazolin versus (flu)cloxacillin regarding 90-day all-cause mortality in the Treatment Policy Strategy population. The x-axis is labeled "Odds ratio (estimand 1)" ranging from 0.4 to 1.5, and the y-axis is labeled "Cefazolin (adults)." The distribution is depicted as a light blue curve, with credible intervals marked at 0.95, 0.99, and 1, indicated by darker shades of blue. A vertical dashed line is at the odds ratio of 1.2.























